LTC1284974I2 - Triazoliltropano dariniai kaip CCR5 moduliatoriai - Google Patents

Triazoliltropano dariniai kaip CCR5 moduliatoriai

Info

Publication number
LTC1284974I2
LTC1284974I2 LTPA2008004C LTPA2008004C LTC1284974I2 LT C1284974 I2 LTC1284974 I2 LT C1284974I2 LT PA2008004 C LTPA2008004 C LT PA2008004C LT PA2008004 C LTPA2008004 C LT PA2008004C LT C1284974 I2 LTC1284974 I2 LT C1284974I2
Authority
LT
Lithuania
Prior art keywords
triazolyltropane
derivatives
ccr5 modulators
ccr5
modulators
Prior art date
Application number
LTPA2008004C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
Phivco-1 Llc,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014046A external-priority patent/GB0014046D0/en
Priority claimed from GB0015835A external-priority patent/GB0015835D0/en
Application filed by Phivco-1 Llc, filed Critical Phivco-1 Llc,
Publication of LTPA2008004I1 publication Critical patent/LTPA2008004I1/lt
Publication of LTC1284974I2 publication Critical patent/LTC1284974I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
LTPA2008004C 2000-05-26 2008-02-25 Triazoliltropano dariniai kaip CCR5 moduliatoriai LTC1284974I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0014046A GB0014046D0 (en) 2000-05-26 2000-05-26 Compounds useful in therapy
GB0015835A GB0015835D0 (en) 2000-06-27 2000-06-27 Compounds useful in therapy
PCT/IB2001/000806 WO2001090106A2 (en) 2000-05-26 2001-05-09 Tryasolyl tropane derivatives as ccr5 modulators

Publications (2)

Publication Number Publication Date
LTPA2008004I1 LTPA2008004I1 (lt) 2020-07-27
LTC1284974I2 true LTC1284974I2 (lt) 2020-11-10

Family

ID=26244452

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2008004C LTC1284974I2 (lt) 2000-05-26 2008-02-25 Triazoliltropano dariniai kaip CCR5 moduliatoriai

Country Status (50)

Country Link
EP (3) EP1990341B1 (Direct)
JP (2) JP3693957B2 (Direct)
KR (2) KR100548854B1 (Direct)
CN (2) CN1279040C (Direct)
AP (1) AP1965A (Direct)
AR (2) AR028622A1 (Direct)
AT (2) ATE260914T1 (Direct)
AU (2) AU2001252482B2 (Direct)
BG (1) BG65966B1 (Direct)
BR (1) BRPI0110955B8 (Direct)
CA (1) CA2408909C (Direct)
CR (1) CR10145A (Direct)
CU (1) CU23288B7 (Direct)
CY (3) CY2008006I2 (Direct)
CZ (1) CZ299102B6 (Direct)
DE (3) DE60135685D1 (Direct)
DK (2) DK1284974T3 (Direct)
DZ (1) DZ3464A1 (Direct)
EA (2) EA005382B1 (Direct)
EE (1) EE05110B1 (Direct)
EG (1) EG24137A (Direct)
ES (3) ES2401812T3 (Direct)
FR (1) FR08C0007I2 (Direct)
GE (1) GEP20063799B (Direct)
HR (1) HRP20020938B1 (Direct)
HU (1) HU225810B1 (Direct)
IL (2) IL152531A0 (Direct)
IS (1) IS2511B (Direct)
LT (1) LTC1284974I2 (Direct)
LU (1) LU91417I2 (Direct)
MA (1) MA26902A1 (Direct)
ME (1) ME00555A (Direct)
MX (1) MXPA02011631A (Direct)
MY (3) MY156920A (Direct)
NL (1) NL300338I2 (Direct)
NO (3) NO327892B1 (Direct)
NZ (1) NZ521477A (Direct)
OA (1) OA12264A (Direct)
PA (1) PA8517101A1 (Direct)
PE (1) PE20011371A1 (Direct)
PL (1) PL200551B1 (Direct)
PT (2) PT1526134E (Direct)
RS (2) RS50904B (Direct)
SI (2) SI1526134T1 (Direct)
SK (1) SK286129B6 (Direct)
TN (1) TNSN01077A1 (Direct)
TR (1) TR200400541T4 (Direct)
TW (1) TWI230160B (Direct)
UY (1) UY26727A1 (Direct)
WO (1) WO2001090106A2 (Direct)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020938B1 (en) * 2000-05-26 2011-05-31 Pfizer Inc. Tropane derivatives useful in therapy
CA2450271A1 (en) * 2001-06-12 2002-12-19 Sk Corporation Novel phenylalkyl diamine and amide analogs
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
GB0208071D0 (en) * 2002-04-08 2002-05-22 Pfizer Ltd Tropane derivatives useful in therapy
RS51550B (sr) * 2002-04-08 2011-06-30 Pfizer Inc. Derivati tropana kao modulatori ccr5
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
BR0309982A (pt) * 2002-05-23 2005-03-22 Pfizer Método para identificação de um ligando, pelo qual o tempo de residência no receptor é medido
ES2311755T3 (es) * 2002-12-13 2009-02-16 Smithkline Beecham Corporation Compuestos de ciclohexilo como antagonistas de ccrs.
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
DE10336274A1 (de) * 2003-08-07 2005-03-10 Honeywell Specialty Chemicals Verfahren zur Herstellung von geminalen Difluoralkanen
US7825147B2 (en) 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
EP1786816A4 (en) 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
MXPA06003749A (es) * 2003-10-03 2006-06-14 Pfizer Derivados de tropano.
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
DK1761542T3 (da) 2004-06-09 2008-04-28 Hoffmann La Roche Octahydropyrrolo[3,4-C] pyrrolderivater og anvendelsen deraf som antivirusmidler
CA2586231A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
KR20080035653A (ko) 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
WO2007144720A2 (en) * 2006-06-12 2007-12-21 Pfizer Products Inc. Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients
EP2057125B1 (en) 2006-08-16 2011-03-30 F. Hoffmann-La Roche AG Non-nucleoside reverse transcriptase inhibitors
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
MX2009005881A (es) 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
US20080146605A1 (en) * 2006-12-19 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
WO2008132128A2 (en) * 2007-04-27 2008-11-06 Solvay (Société Anonyme) Synthesis of a pharmaceutically active compound
RU2368613C1 (ru) * 2008-02-19 2009-09-27 Институт молекулярной генетики Российской Академии наук (ИМГ РАН) (Статус Государственного учреждения) Равномерно меченный тритием 4,4-дифтор-n-{(1s)-3-[3-(3-изопропил-5-метил-4н-1,2,4-триазол-4-ил)-8-азабицикло[3.2.1]окт-8-ил]-1-фенилпропил}циклогексан карбодиимид
CA2716838C (en) * 2008-02-29 2014-01-07 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
EP2456309B1 (en) * 2009-07-24 2015-12-23 GlaxoSmithKline LLC Azabicyclo[3.2.1]octyl derivatives for use in the treatment of HIV.
CN102140104B (zh) * 2010-02-03 2014-11-12 中国科学院上海药物研究所 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
MX2012011415A (es) 2010-04-02 2013-02-26 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
CN103159754A (zh) * 2011-12-19 2013-06-19 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CZ306455B6 (cs) 2013-04-26 2017-02-01 Zentiva, K.S. Nový způsob syntézy Maravirocu
CN103497164B (zh) * 2013-09-23 2015-12-23 西安近代化学研究所 一种蒽衍生物及其制备方法
CN104304248B (zh) * 2014-10-23 2016-08-10 西北农林科技大学 3-芳基丙酸酯类化合物作为制备杀螨药物的应用
CN104402883B (zh) * 2014-10-24 2016-04-27 艾琪康医药科技（上海）有限公司 4，4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途
CN104387379B (zh) * 2014-11-26 2017-01-11 扬州氟药科技有限公司 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
CN107879963A (zh) 2016-09-29 2018-04-06 中国科学院上海药物研究所 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
EE03877B1 (et) * 1994-04-19 2002-10-15 Neurosearch A/S Tropaan-2-aldoksiimi derivaadid neurotransmitteritagasihaarde inhibiitoritena
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6281212B1 (en) * 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU5604998A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2296314A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
WO1999037619A1 (en) * 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
HRP20020938B1 (en) * 2000-05-26 2011-05-31 Pfizer Inc. Tropane derivatives useful in therapy

Also Published As

Publication number Publication date
CN1437599A (zh) 2003-08-20
JP4854970B2 (ja) 2012-01-18
EE200200656A (et) 2004-06-15
NO20025227L (no) 2002-10-31
CY2022009I1 (el) 2022-05-27
HUP0302474A3 (en) 2007-05-29
EA005382B1 (ru) 2005-02-24
RS51436B (sr) 2011-04-30
HK1054927A1 (en) 2003-12-19
NL300338I2 (nl) 2008-06-02
HRP20020938B1 (en) 2011-05-31
NO2010007I2 (no) 2013-09-09
EG24137A (en) 2008-08-06
KR100523501B1 (ko) 2005-10-25
CZ20023806A3 (cs) 2004-01-14
ME00555B (me) 2011-12-20
PA8517101A1 (es) 2002-10-24
HK1078573A1 (en) 2006-03-17
JP2005194283A (ja) 2005-07-21
AU2001252482C1 (en) 2001-12-03
NZ521477A (en) 2004-07-30
NO327892B1 (no) 2009-10-12
IS2511B (is) 2009-05-15
HRP20020938A2 (en) 2005-02-28
DE60102233T2 (de) 2005-01-27
DE122008000011I1 (de) 2008-06-05
EA007580B1 (ru) 2006-12-29
LU91417I9 (Direct) 2019-01-02
TR200400541T4 (tr) 2004-04-21
MXPA02011631A (es) 2003-03-27
ME00555A (en) 2011-12-20
DE60135685D1 (de) 2008-10-16
EA200401056A1 (ru) 2005-04-28
ES2215129T3 (es) 2004-10-01
GEP20063799B (en) 2006-04-25
BG65966B1 (bg) 2010-07-30
BR0110955A (pt) 2003-06-03
YU82202A (sh) 2005-11-28
DE60102233D1 (de) 2004-04-08
CN100355753C (zh) 2007-12-19
TNSN01077A1 (fr) 2005-11-10
EP1990341B1 (en) 2013-01-23
BRPI0110955B1 (pt) 2016-06-28
PL359267A1 (en) 2004-08-23
CN1279040C (zh) 2006-10-11
BG107140A (bg) 2003-05-30
WO2001090106A3 (en) 2002-03-28
CA2408909C (en) 2006-06-27
WO2001090106A2 (en) 2001-11-29
SI1284974T1 (en) 2004-08-31
EP1526134B1 (en) 2008-09-03
CN1680371A (zh) 2005-10-12
MY131019A (en) 2007-07-31
UY26727A1 (es) 2001-12-28
CY2008006I1 (el) 2009-11-04
ATE260914T1 (de) 2004-03-15
PT1526134E (pt) 2008-10-28
KR100548854B1 (ko) 2006-02-02
AP2002002663A0 (en) 2002-12-31
MA26902A1 (fr) 2004-12-20
NO2010007I1 (no) 2010-04-08
HK1090836A1 (en) 2007-01-05
OA12264A (en) 2003-11-10
NL300338I1 (nl) 2008-05-01
MY153023A (en) 2014-12-31
CY2008006I2 (el) 2009-11-04
JP3693957B2 (ja) 2005-09-14
DZ3464A1 (Direct) 2001-11-29
TWI230160B (en) 2005-04-01
EP1526134A3 (en) 2006-11-29
HU225810B1 (en) 2007-10-29
RS20090438A (sr) 2010-05-07
BRPI0110955B8 (pt) 2021-05-25
LTPA2008004I1 (lt) 2020-07-27
AP1965A (en) 2009-03-04
IL152531A0 (en) 2003-05-29
CZ299102B6 (cs) 2008-04-23
KR20030004417A (ko) 2003-01-14
LU91417I2 (fr) 2008-04-22
PE20011371A1 (es) 2002-01-18
CA2408909A1 (en) 2001-11-29
FR08C0007I2 (fr) 2009-01-15
EP1284974B1 (en) 2004-03-03
CR10145A (es) 2008-08-19
JP2003534343A (ja) 2003-11-18
EP1526134A2 (en) 2005-04-27
EE05110B1 (et) 2008-12-15
ATE407134T1 (de) 2008-09-15
IS6565A (is) 2002-09-24
FR08C0007I1 (Direct) 2008-04-25
ES2311126T3 (es) 2009-02-01
SI1526134T1 (sl) 2008-12-31
EA200201141A1 (ru) 2003-04-24
DK1284974T3 (da) 2004-06-07
SK16432002A3 (sk) 2004-01-08
HUP0302474A2 (hu) 2003-11-28
AU2001252482B2 (en) 2006-01-19
CY2022009I2 (el) 2022-05-27
PL200551B1 (pl) 2009-01-30
NO20025227D0 (no) 2002-10-31
AU5248201A (en) 2001-12-03
SK286129B6 (sk) 2008-04-07
IL152531A (en) 2010-05-17
KR20050046743A (ko) 2005-05-18
AR028622A1 (es) 2003-05-14
CY1108451T1 (el) 2014-04-09
DK1526134T3 (da) 2008-11-17
NO2020019I1 (no) 2020-06-30
ES2401812T3 (es) 2013-04-24
AR060159A2 (es) 2008-05-28
MY156920A (en) 2016-04-15
EP1284974A2 (en) 2003-02-26
EP1990341A1 (en) 2008-11-12
PT1284974E (pt) 2004-06-30
RS50904B (sr) 2010-08-31
CU23288B7 (es) 2008-06-30

Similar Documents

Publication Publication Date Title
LTPA2008004I1 (lt) Triazoliltropano dariniai kaip CCR5 moduliatoriai
ID28965A (id) Azabisikloalkana sebagai modulator ccr5
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
ID29031A (id) Piperidin sebagai modulator ccr5
NO20025590L (no) Fenylglycin-derivater
ATE540013T1 (de) Naphthalinderivate
PT1303521E (pt) Derivados de tetra-hidro-heterocicloazepinil-pirimidina
DK1280809T3 (da) Antitumorecteinascidinderivater
ATE298332T1 (de) Decahydro-isochinolinderivate
NO20023770L (no) Indol-3-ylderivater
DK1368299T3 (da) Substituerede C-cyclohexylmethylaminderivater
AR028602A1 (es) Derivados de pirrol
AR028282A1 (es) Derivados de aminofenil pirimidona
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
ATE280752T1 (de) Aminomethyl-phenyl-cyclohexanonderivate
DE50112454D1 (de) Substituierte 5-amino-1-penten-3-ol-derivate
ATE374776T1 (de) Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no) 2-fenylpyran-4-on-derivater
DOP2000000093A (es) Derivados de benzamina
DK1246793T3 (da) Substituerede aminomethyl-phenyl-cyclohexanderivater
FI4879U1 (fi) Kiertoilmakiuas